Can Vaccine Manufacturers Be Held Liable for Adverse Reactions? Supreme Court Clarifies
Prakash Bang vs Glaxo Smithkline Pharmaceuticals Ltd. & Anr.
Listen to this judgment
• 4 min readKey Takeaways
• A court cannot hold a vaccine manufacturer liable for adverse reactions merely because a patient claims to have suffered from them.
• Section 2(1)(g) of the Consumer Protection Act applies when a complainant establishes a direct link between the product and the adverse effect.
• Evidence of adverse reactions must be supported by medical documentation and expert testimony to substantiate claims.
• The burden of proof lies with the complainant to demonstrate that the vaccine caused the alleged injury.
• Minimal incidence of adverse reactions does not automatically imply negligence or deficiency in service by the manufacturer.
Introduction
In a significant ruling, the Supreme Court of India addressed the liability of vaccine manufacturers in cases of alleged adverse reactions. The case of Prakash Bang vs. Glaxo Smithkline Pharmaceuticals Ltd. & Anr. raised critical questions about the burden of proof required to establish a direct link between a vaccine and the injuries claimed by a complainant. The Court's decision underscores the necessity for substantial evidence in consumer protection claims involving medical products.
Case Background
The appellant, Prakash Bang, approached the Supreme Court challenging the order of the National Consumer Disputes Redressal Commission (NCDRC), which had dismissed his complaint against Glaxo Smithkline Pharmaceuticals. Bang alleged that he suffered severe pain and permanent disability in his shoulder following the administration of the Engerix-B vaccine, intended to provide immunity against Hepatitis B. He claimed that the vaccine caused 'myositis,' a condition he attributed to the vaccine's adverse effects.
The NCDRC found that Bang failed to establish any defect in the vaccine or negligence on the part of the manufacturer. The Commission noted that while Bang experienced pain after vaccination, his family members who received the same vaccine did not report any adverse reactions. This raised questions about the causal link between the vaccine and Bang's condition.
What The Lower Authorities Held
The NCDRC concluded that Bang did not provide sufficient evidence to support his claims. The Commission highlighted that the incidence of myositis related to the vaccine was minimal, with only nine reported cases worldwide, indicating a frequency of 0.02 per million doses. The NCDRC emphasized that the burden of proof rested with Bang to demonstrate that his condition was directly caused by the vaccine, which he failed to do.
The Court's Reasoning
The Supreme Court, while reviewing the NCDRC's decision, focused on two primary issues: whether Bang had sufficiently proven that he suffered from myositis and whether the absence of myositis in the vaccine's literature constituted a deficiency in service. The Court noted that Bang did not provide adequate medical evidence to establish that his condition was caused by the vaccine. The affidavits submitted by his family doctor and uncle were deemed insufficient as they lacked substantive medical backing.
The Court pointed out that the family doctor, who administered the vaccine, did not provide any detailed medical analysis or literature to support the claim that the vaccine caused myositis. Furthermore, the Court observed that the absence of adverse reactions in Bang's family members, who received the same vaccine, weakened his case. The Court concluded that the NCDRC's findings were not erroneous or perverse and upheld the dismissal of Bang's complaint.
Statutory Interpretation
The ruling involved an interpretation of the Consumer Protection Act, particularly Section 2(1)(g), which defines 'deficiency in service.' The Court clarified that for a claim of deficiency to succeed, the complainant must establish a direct link between the product and the alleged adverse effect. The minimal incidence of myositis, as noted in the NCDRC's findings, did not meet the threshold for establishing negligence or deficiency in service.
Why This Judgment Matters
This judgment is significant for several reasons. Firstly, it reinforces the principle that the burden of proof lies with the complainant in cases involving medical products. It emphasizes the necessity for substantial evidence, including medical documentation and expert testimony, to support claims of adverse reactions. The ruling also clarifies that minimal incidences of adverse reactions do not automatically imply negligence on the part of manufacturers, thereby providing a degree of protection to pharmaceutical companies against unfounded claims.
Final Outcome
The Supreme Court dismissed the appeal filed by Prakash Bang, affirming the NCDRC's decision and ruling that the appellant had failed to establish a causal link between the vaccine and his alleged injuries. The Court's ruling underscores the importance of evidence in consumer protection cases involving medical products and sets a precedent for future claims.
Case Details
- Case Title: Prakash Bang vs Glaxo Smithkline Pharmaceuticals Ltd. & Anr.
- Citation: 2023INSC794
- Court: IN THE SUPREME COURT OF INDIA
- Bench: Justice A.S. Bopanna, Justice Prashant Kumar Mishra
- Date of Judgment: 2023-09-05
